Study of ublituximab injection for multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing multiple sclerosis (RMS).
- Your disability level is moderate (EDSS score 5.5 or less at screening).
- You have been neurologically stable for at least 30 days before the study starts.
- If you are a woman who could become pregnant, you must use effective birth control during the study and for 6 months after your last dose.
- You cannot have primary progressive MS or inactive secondary progressive MS.
- You cannot have any other active immune system disorder or immune deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.